(Q40261250)

19 September 2017

title

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans (English)

1 reference

19 September 2017

1 reference

1 reference

6

1 reference

19 September 2017

1

François Helle

1 reference

19 September 2017

5

Cécile Voisset

1 reference

19 September 2017

Czeslaw Wychowski

2

1 reference

19 September 2017

Ngoc Vu-Dac

series ordinal

3

1 reference

19 September 2017

Kirk R Gustafson

series ordinal

4

1 reference

19 September 2017

language of work or name

English

0 references

publication date

29 June 2006

1 reference

Journal of Biological Chemistry

19 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

19 September 2017

volume

281

1 reference

19 September 2017

issue

35

1 reference

19 September 2017

page(s)

25177-25183

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Glycosylation of hepatitis C virus envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Characterization of functional hepatitis C virus envelope glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Hepatitis C virus entry: potential receptors and their biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Challenges and successes in developing new therapies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Therapy of hepatitis C: from empiricism to eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Hepatitis C virus genetic variability: pathogenic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M602431200

21 January 2018

Identifiers

DOI

10.1074/JBC.M602431200

1 reference

19 September 2017

1 reference